Prospective evaluation of an anti-cancer drugs management programme in a dedicated oral therapy center (DICTO programme).
Cancer
Co-ordination
Multidisciplinary management
Oral therapies
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
25 Jul 2020
25 Jul 2020
Historique:
received:
18
05
2020
accepted:
16
07
2020
entrez:
27
7
2020
pubmed:
28
7
2020
medline:
25
6
2021
Statut:
epublish
Résumé
Oral therapies have highly modified cancer patient management and changed hospital practises. We introduce a specific Oral Therapy Centre and retrospectively review information prospectively recorded by co-ordination nurses (CNs) (the DICTO programme). We describe the roles played by CNs in the management of oral cancer therapies at Limoges Dupuytren Hospital between May 2015 and June 2018. All cancers, irrespective of stage or whether oral general chemotherapy or targeted therapy was prescribed, are included. We followed up 287 patients of median age 67 years (range 26-89 years). Of these, 76% had metastases and 44% were on first-line therapy. The vast majority (88%) of their first CN contacts occurred just after physician consultation and lasted an average of 60 min. As part of follow-up, the CNs made 2719 calls (average 10 min) to patients to educate them and to verify compliance and drug tolerance. They also received 833 calls from patients (70%) or their relatives or health professionals (30%) seeking advice on management of side effects. In addition to the initial appointments, 1069 non-scheduled follow-up visits were made to assess side effects (49.2%). The CNs devoted 5 h to each patient over 3 months of treatment (i.e. 25 min/day) and, also organised scheduled hospitalisations in the department of oncology for 51% of patients. We show the interest and real-life work in a specific oral therapy centre within oncology department with the role of CNs to facilitate the global health care of the patients.
Identifiants
pubmed: 32712771
doi: 10.1007/s12032-020-01393-7
pii: 10.1007/s12032-020-01393-7
pmc: PMC7382654
doi:
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
69Références
Palliat Support Care. 2020 Apr;18(2):141-147
pubmed: 31535613
J Oncol Pharm Pract. 2016 Jun;22(3):511-6
pubmed: 25900102
J Oncol Pract. 2017 May;13(5):e474-e485
pubmed: 28398843
J Clin Oncol. 1997 Jan;15(1):110-5
pubmed: 8996131
Ann Oncol. 2006 Feb;17(2):239-45
pubmed: 16344278
Pharmacol Res. 2017 Jul;121:138-144
pubmed: 28473246
Cancer Metastasis Rev. 2015 Sep;34(3):497-509
pubmed: 26250585
Clin Breast Cancer. 2020 Jun;20(3):201-208
pubmed: 32201165
Support Care Cancer. 2016 Mar;24(3):1261-8
pubmed: 26306518
Patient Prefer Adherence. 2014 Jun 25;8:917-23
pubmed: 25028540
JAMA Oncol. 2018 Jan 1;4(1):105-117
pubmed: 28570732
Semin Oncol Nurs. 2011 May;27(2):133-41
pubmed: 21514482
Eur J Cancer Care (Engl). 2014 Jan;23(1):22-35
pubmed: 24079854
PLoS One. 2014 Dec 11;9(12):e115060
pubmed: 25503576
BMC Health Serv Res. 2017 Feb 13;17(1):133
pubmed: 28193214
Eur J Oncol Nurs. 2018 Oct;36:16-25
pubmed: 30322505
Int J Nurs Stud. 2014 Mar;51(3):495-510
pubmed: 24074939
Eur J Cancer Care (Engl). 2013 May;22(3):413-9
pubmed: 23527965
Saudi Pharm J. 2017 Jan;25(1):136-140
pubmed: 28223874
J Natl Compr Canc Netw. 2019 Mar 1;17(3):221-228
pubmed: 30865917
J Am Pharm Assoc (2003). 2008 Sep-Oct;48(5):632-9
pubmed: 18826902
Cancer Nurs. 2019 Jan/Feb;42(1):20-34
pubmed: 28926349
Bull Cancer. 2017 Sep;104(9):727-734
pubmed: 28778339
Bull Cancer. 2019 Sep;106(9):734-746
pubmed: 31130274